Cipla has entered into a strategic distribution, supply and development agreement with the US-based BioQ Pharma for registration and commercialisation of the latter’s Ropivacaine infusion system, used in treating post-operative pain, in India.
The Ropivacaine infusion system is pre-filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous-infusion post-operative pain solution. BioQ Pharma’s unit-dose infusion pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care.
Cipla’s proven, hospital-focused sales and marketing organisation will be essential in introducing BioQ Pharma’s proprietary unit-dose, large volume infusion pharmaceuticals to India’s healthcare market.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.15 |
| Dr. Reddys Lab | 1236.65 |
| Cipla | 1236.45 |
| Zydus Lifesciences | 938.75 |
| Lupin | 2328.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: